Tom 6, Nr 1 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-05-12
Wyświetlenia strony
4036
Wyświetlenia/pobrania artykułu
675
Postępowanie w raku trzonu macicy z uwzględnieniem klasyfikacji molekularnej — zalecenia ESGO/ESTRO/ESP 2020
1
, 23, 1, 1, 1
, 23, 1, 1, 1
Ginekologia i Perinatologia Praktyczna 2021;6(1):1-8.
Streszczenie
Na początku lat 80. XX wieku Bokhman przedstawił podział raka trzonu macicy na 2 typy: endometriodny i nieendometrioidny. Chociaż zarówno ginekolodzy, jak i patolodzy w dalszym ciągu stosują go jeszcze w praktyce klinicznej, to ma on już znaczenie historyczne. W minionej dekadzie dokonał się ogromny postęp w diagnostyce raka trzonu macicy poprzez wprowadzenie metod molekularnych oraz immunohistochemicznych. Doprowadziło to do wyodrębnienia 5 nowych typów raka trzonu macicy (ultramutated, hypermutated, high copy number, low copy number, multiple classifier) o odmiennym przebiegu klinicznym oraz różnym rokowaniu. W artykule przedstawiono zalecenia postępowania ESGO/ESTRO/ESP 2020 w raku trzonu macicy z uwzględnieniem nowej klasyfikacji molekularnej.
Słowa kluczowe: rak endometriumklasyfikacja molekularnaleczenie
Referencje
- Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1): 12–39.
- Ryan NAJ, Glaire MA, Blake D, et al. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med. 2019; 21(10): 2167–2180.
- Cho KR, Cooper K, Croce S, et al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2019; 38 Suppl 1: S114–S122.
- Mills AM, Liou S, Ford JM, et al. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol. 2014; 38(11): 1501–1509.
- Mojtahed A, Schrijver I, Ford JM, et al. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011; 24(7): 1004–1014.
- Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009; 33(11): 1639–1645.
- Møller P, Seppälä T, Bernstein I, et al. Mallorca Group (http://mallorca-group.eu). Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017; 66(3): 464–472.
- Stelloo E, Nout RA, Osse EM, et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res. 2016; 22(16): 4215–4224.
- León-Castillo A, Boer Sde, Powell M, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology. 2020; 38(29): 3388–3397.
- Kommoss FKf, Karnezis AN, Kommoss F, et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018; 119(4): 480–486.
- van der Putten LJm, Visser NCm, van de Vijver K, et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer. 2016; 115(6): 716–724.
- Van Gool IC, Stelloo E, Nout RA, et al. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Mod Pathol. 2016; 29(2): 174–181.
- WHO Classification of Tumours. Female genital organ tumours, International agency for research on cancer IARC. 5th edn. Lyon. 2020.
- Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol. 2007; 26(2): 115–123.
- Luomaranta A, Leminen A, Loukovaara M. Magnetic resonance imaging in the assessment of high-risk features of endometrial carcinoma: a meta-analysis. Int J Gynecol Cancer. 2015; 25(5): 837–842.
- Andreano A, Rechichi G, Rebora P, et al. MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis. Eur Radiol. 2014; 24(6): 1327–1338.
- Alcázar J, Gastón B, Navarro B, et al. Transvaginal ultrasound versus magnetic resonance imaging for preoperative assessment of myometrial infiltration in patients with endometrial cancer: a systematic review and meta-analysis. Journal of Gynecologic Oncology. 2017; 28(6).
- Janda M, Gebski V, Davies LC, et al. Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial. JAMA. 2017; 317(12): 1224–1233.
- Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012; 30(7): 695–700.
- Signorelli M, Lissoni AA, Cormio G, et al. Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study. Ann Surg Oncol. 2009; 16(12): 3431–3441.
- Liu T, Tu H, Li Y, et al. Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis. Ann Surg Oncol. 2019; 26(9): 2933–2942.
- Kaban A, Topuz S, Erdem B, et al. Is Omentectomy Necessary for Non-Endometrioid Endometrial Cancer. Gynecol Obstet Invest. 2018; 83(5): 482–486.
- Joo WD, Schwartz PE, Rutherford TJ, et al. Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis. Ann Surg Oncol. 2015; 22(11): 3695–3700.
- Lee B, Suh DH, Kim K, et al. Influence of positive peritoneal cytology on prognostic factors and survival in early-stage endometrial cancer: a systematic review and meta-analysis. Jpn J Clin Oncol. 2016; 46(8): 711–717.
- Kim CH, Khoury-Collado F, Barber EL, et al. Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol. 2013; 131(3): 714–719.
- Rozenholc A, Samouelian V, Warkus T, et al. Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer. Gynecol Oncol. 2019; 153(3): 500–504.
- de Boer SM, Powell ME, Mileshkin L, et al. PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018; 19(3): 295–309.
- Matei D, Filiaci V, Randall ME, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019; 380(24): 2317–2326.
- de Boer SM, Powell ME, Mileshkin L, et al. PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019; 20(9): 1273–1285.
- Albeesh R, Turgeon GA, Alfieri J, et al. Adjuvant therapy in stage III endometrial cancer confined to the pelvis. Gynecol Oncol. 2019; 152(1): 26–30.
- Scharl S, Papathemelis T, Kronberger K, et al. Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry. Arch Gynecol Obstet. 2018; 297(5): 1245–1253.
- Bogani G, Cromi A, Serati M, et al. Chemotherapy reduces para-aortic node recurrences in endometrial cancer with positive pelvic and unknown para-aortic nodes. Int J Gynecol Cancer. 2015; 25(2): 263–268.
- Rajkumar S, Nath R, Lane G, et al. Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival. Eur J Obstet Gynecol Reprod Biol. 2019; 234: 26–31.
- de Lange NM, Ezendam NPM, Kwon JS, et al. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. Curr Oncol. 2019; 26(2): e226–e232.
- Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer - PubMed. https://pubmed.ncbi.nlm.nih.gov (31 Jan 2021).
